Effects of the macrolide drug tylosin on chronic diarrhea in rhesus macaques (Macaca mulatta).
Diarrhea is the gastrointestinal disease most frequently encountered in captive rhesus macaques. The precise pathogenic mechanisms underlying chronic diarrhea in nonhuman primates are not well understood, but a persistent inflammatory component has been implicated strongly. This study evaluated the inflammatory changes in the colon of macaques with diarrhea and assessed the efficacy of a 10-d course of tylosin in a cohort of 21 animals with chronic diarrhea. Stool quality was evaluated daily, and fecal consistency was scored. Colonoscopies were performed; biopsy samples were characterized histologically and assayed for expression of TNFalpha mRNA. Blood samples collected pre-, mid-, and post-treatment were assayed for C-reactive protein (CRP). The results indicated that 63% of the animals receiving tylosin showed improvement in stool quality, compared with 10% in the sham-treated group. Histologically, 82% of animals in the tylosin-treated group had a reduction in the severity of colonic lesions post-treatment, compared with 40% of animals in the sham group. The amount of TNFalpha mRNA before treatment did not differ from that afterward in either tylosin- or sham-treated animals. CRP levels serially decreased in tylosin-treated monkeys; the average post-treatment CRP value for tylosin-treated animals was 11.96 +/- 3.86 microg/ml compared with 26.48 +/- 4.86 microg/ml for sham-treated controls. In conclusion, tylosin significantly improved the fecal consistency score, significantly decreased colonic inflammation, and significantly decreased serum CRP levels post-treatment in rhesus macaques with chronic diarrhea.
Blackwood
Rebecca S
RS
California National Primate Research Center, University of California, Davis, CA, USA. rsblackwood@primate.ucdavis.edu
Tarara
Ross P
RP
Christe
Kari L
KL
Spinner
Abigail
A
Lerche
Nicholas W
NW
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002097:C-Reactive Protein / Q000378:metabolism; D002908:Chronic Disease; D003113:Colonoscopy / Q000662:veterinary; D016207:Cytokines / Q000235:genetics; D003967:Diarrhea / Q000188:drug therapy* / Q000382:microbiology / Q000662:veterinary; D004195:Disease Models, Animal; D004283:Dog Diseases / Q000382:microbiology; D004285:Dogs; D005243:Feces / Q000382:microbiology; D005786:Gene Expression Regulation; D008253:Macaca mulatta; D008795:Metronidazole / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D018419:Primate Diseases / Q000188:drug therapy / Q000382:microbiology; D012333:RNA, Messenger / Q000097:blood / Q000235:genetics; D013752:Tetracycline / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics; D015645:Tylosin / Q000627:therapeutic use*
D000900:Anti-Bacterial Agents; D016207:Cytokines; D012333:RNA, Messenger; D014409:Tumor Necrosis Factor-alpha; D008795:Metronidazole; D002097:C-Reactive Protein; D013752:Tetracycline; D011241:Prednisone; D015645:Tylosin